Literature DB >> 11553595

Orally administered Giardia duodenalis extracts enhance an antigen-specific antibody response.

L A Dunn1, J A Upcroft, E V Fowler, B S Matthews, P Upcroft.   

Abstract

We have identified novel adjuvant activity in specific cytosol fractions from trophozoites of Giardia isolate BRIS/95/HEPU/2041 (J. A. Upcroft, P. A. McDonnell, and P. Upcroft, Parasitol. Today, 14:281-284, 1998). Adjuvant activity was demonstrated in the systemic and mucosal compartments when Giardia extract was coadministered orally with antigen to mice. Enhanced antigen-specific serum antibody responses were demonstrated by enzyme-linked immunosorbent assay to be comparable to those generated by the "gold standard," mucosal adjuvant cholera toxin. A source of adjuvant activity was localized to the cytosolic component of the parasite. Fractionation of the cytosol produced fraction pools, some of which, when coadministered with antigen, stimulated an enhanced antigen-specific serum response. The toxic component of conventional mucosal adjuvants is associated with adjuvant activity; therefore, in a similar way, the toxin-like attributes of BRIS/95/HEPU/2041 may be responsible for its adjuvanticity. Complete characterization of the adjuvant is under way.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553595      PMCID: PMC98786          DOI: 10.1128/IAI.69.10.6503-6510.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

Review 1.  Improving vaccine performance with adjuvants.

Authors:  F R Vogel
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

Review 2.  Strategies for mucosal vaccine development.

Authors:  P N Boyaka; M Marinaro; J L Vancott; I Takahashi; K Fujihashi; M Yamamoto; F W van Ginkel; R J Jackson; H Kiyono; J R McGhee
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

Review 3.  Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion.

Authors:  C L Sears; J B Kaper
Journal:  Microbiol Rev       Date:  1996-03

4.  Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.

Authors:  K Tochikubo; M Isaka; Y Yasuda; S Kozuka; K Matano; Y Miura; T Taniguchi
Journal:  Vaccine       Date:  1998 Jan-Feb       Impact factor: 3.641

5.  Lethal Giardia from a wild-caught sulphur-crested cockatoo (Cacatua galerita) established in vitro chronically infects mice.

Authors:  J A Upcroft; P A McDonnell; A N Gallagher; N Chen; P Upcroft
Journal:  Parasitology       Date:  1997-05       Impact factor: 3.234

6.  Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity.

Authors:  S Crotty; B L Lohman; F X Lü; S Tang; C J Miller; R Andino
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

7.  The activity of drugs against Giardia intestinalis in neonatal mice.

Authors:  P F Boreham; R E Phillips; R W Shepherd
Journal:  J Antimicrob Chemother       Date:  1986-09       Impact factor: 5.790

Review 8.  Vaccines for mucosal immunity to combat emerging infectious diseases.

Authors:  F W van Ginkel; H H Nguyen; J R McGhee
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

Review 9.  Mucosal immunity and tolerance: relevance to vaccine development.

Authors:  C Czerkinsky; F Anjuere; J R McGhee; A George-Chandy; J Holmgren; M P Kieny; K Fujiyashi; J F Mestecky; V Pierrefite-Carle; C Rask; J B Sun
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

10.  A novel bioadhesive intranasal delivery system for inactivated influenza vaccines.

Authors:  M Singh; M Briones; D T O'Hagan
Journal:  J Control Release       Date:  2001-02-23       Impact factor: 9.776

View more
  6 in total

1.  Antibody and cytokine responses to Giardia excretory/secretory proteins in Giardia intestinalis-infected BALB/c mice.

Authors:  Juan C Jiménez; Josette Fontaine; Colette Creusy; Laurence Fleurisse; Jean-Marie Grzych; Monique Capron; Eduardo Dei-Cas
Journal:  Parasitol Res       Date:  2014-05-28       Impact factor: 2.289

2.  Lactobacillus johnsonii La1 antagonizes Giardia intestinalis in vivo.

Authors:  Martín A Humen; Graciela L De Antoni; Jalil Benyacoub; María E Costas; Marta I Cardozo; Leonora Kozubsky; Kim-Yen Saudan; Angele Boenzli-Bruand; Stephanie Blum; Eduardo J Schiffrin; Pablo F Pérez
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

3.  Disruption of antigenic variation is crucial for effective parasite vaccine.

Authors:  Fernando D Rivero; Alicia Saura; Cesar G Prucca; Pedro G Carranza; Alessandro Torri; Hugo D Lujan
Journal:  Nat Med       Date:  2010-04-25       Impact factor: 53.440

4.  Systemic and mucosal responses to oral administration of excretory and secretory antigens from Giardia intestinalis.

Authors:  Juan Carlos Jiménez; Josette Fontaine; Jean-Marie Grzych; Eduardo Dei-Cas; Monique Capron
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

5.  Probiotic Lactobacillus rhamnosus GG modulates the mucosal immune response in Giardia intestinalis-infected BALB/c mice.

Authors:  Nisha Goyal; Geeta Shukla
Journal:  Dig Dis Sci       Date:  2012-12-21       Impact factor: 3.199

6.  Data from a proteomic baseline study of Assemblage A in Giardia duodenalis.

Authors:  Samantha J Emery; Ernest Lacey; Paul A Haynes
Journal:  Data Brief       Date:  2015-08-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.